Shanghai Long Term Debt vs Good Will Analysis

601607 Stock

21.75 0.07 0.32%

Shanghai Pharmaceuticals financial indicator trend analysis is much more than just breaking down Shanghai Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Shanghai Pharmaceuticals is a good investment. Please check the relationship between Shanghai Pharmaceuticals Long Term Debt and its Good Will accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Shanghai Pharmaceuticals Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Long Term Debt vs Good Will

Long Term Debt vs Good Will Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Shanghai Pharmaceuticals Long Term Debt account and Good Will. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Shanghai Pharmaceuticals' Long Term Debt and Good Will is 0.8. Overlapping area represents the amount of variation of Long Term Debt that can explain the historical movement of Good Will in the same time period over historical financial statements of Shanghai Pharmaceuticals Holding, assuming nothing else is changed. The correlation between historical values of Shanghai Pharmaceuticals' Long Term Debt and Good Will is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt of Shanghai Pharmaceuticals Holding are associated (or correlated) with its Good Will. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Good Will has no effect on the direction of Long Term Debt i.e., Shanghai Pharmaceuticals' Long Term Debt and Good Will go up and down completely randomly.

Correlation Coefficient

0.8

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Long Term Debt

Long-term debt is a debt that Shanghai Pharmaceuticals has held for over one year. Long-term debt appears on Shanghai Pharmaceuticals Holding balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Shanghai Pharmaceuticals Holding balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Good Will

An intangible asset that arises when a company acquires another business for more than the fair market value of its net identifiable assets, representing the value of the brand, customer base, and other intangible factors.

Most indicators from Shanghai Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Shanghai Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Shanghai Pharmaceuticals Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

The current year's Selling General Administrative is expected to grow to about 16.4 B, whereas Tax Provision is forecasted to decline to about 1.6 B.

	2021	2022	2023	2024 (projected)
Operating Income	7.9B	8.8B	9.6B	10.0B
Total Revenue	215.8B	232.0B	260.3B	273.3B

Operating Income Total Revenue

Shanghai Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Accounts Payable	Cash	Other Assets	Long Term Debt	Net Receivables	Short Term Investments	Inventory	Other Current Assets	Total Liab	Intangible Assets	Common Stock	Property Plant Equipment	Other Liab	Good Will	Net Tangible Assets	Other Stockholder Equity	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Total Current Assets	Short Term Debt
Total Assets		0.66	1.0	0.98	0.99	0.99	0.97	0.78	0.72	1.0	0.89	0.99	0.37	1.0	0.69	0.83	0.99	0.98	0.85	0.85	-0.51	0.66	0.89	0.92	0.92	0.85
Other Current Liab	0.66		0.66	0.58	0.72	0.65	0.6	0.72	0.66	0.69	0.76	0.64	0.85	0.69	0.49	0.4	0.73	0.69	0.92	0.62	-0.73	0.88	0.77	0.75	0.66	0.87
Total Current Liabilities	1.0	0.66		0.97	0.99	0.99	0.96	0.77	0.71	1.0	0.9	0.99	0.37	1.0	0.67	0.8	0.99	0.98	0.84	0.86	-0.51	0.67	0.9	0.92	0.92	0.86
Total Stockholder Equity	0.98	0.58	0.97		0.97	0.99	0.98	0.72	0.65	0.97	0.81	0.98	0.29	0.97	0.75	0.9	0.96	0.95	0.79	0.82	-0.4	0.54	0.83	0.86	0.88	0.77
Retained Earnings	0.99	0.72	0.99	0.97		0.99	0.95	0.8	0.73	0.99	0.89	0.98	0.46	0.99	0.67	0.79	0.99	0.98	0.88	0.85	-0.52	0.7	0.9	0.92	0.91	0.88
Accounts Payable	0.99	0.65	0.99	0.99	0.99		0.96	0.8	0.73	0.99	0.86	1.0	0.4	0.99	0.68	0.85	0.98	0.96	0.85	0.82	-0.51	0.64	0.87	0.9	0.89	0.84
Cash	0.97	0.6	0.96	0.98	0.95	0.96		0.68	0.62	0.95	0.83	0.96	0.29	0.96	0.79	0.91	0.95	0.94	0.78	0.82	-0.43	0.59	0.82	0.84	0.87	0.77
Other Assets	0.78	0.72	0.77	0.72	0.8	0.8	0.68		0.83	0.82	0.77	0.8	0.63	0.79	0.38	0.59	0.81	0.75	0.82	0.57	-0.78	0.74	0.8	0.81	0.66	0.83
Long Term Debt	0.72	0.66	0.71	0.65	0.73	0.73	0.62	0.83		0.75	0.82	0.75	0.49	0.75	0.36	0.46	0.73	0.68	0.8	0.53	-0.83	0.74	0.71	0.81	0.68	0.81
Net Receivables	1.0	0.69	1.0	0.97	0.99	0.99	0.95	0.82	0.75		0.91	0.99	0.43	1.0	0.66	0.8	0.99	0.98	0.87	0.84	-0.56	0.7	0.9	0.93	0.91	0.88
Short Term Investments	0.89	0.76	0.9	0.81	0.89	0.86	0.83	0.77	0.82	0.91		0.88	0.47	0.92	0.59	0.58	0.91	0.88	0.88	0.77	-0.76	0.85	0.86	0.9	0.88	0.89
Inventory	0.99	0.64	0.99	0.98	0.98	1.0	0.96	0.8	0.75	0.99	0.88		0.38	0.99	0.68	0.85	0.97	0.96	0.85	0.81	-0.53	0.64	0.87	0.91	0.9	0.84
Other Current Assets	0.37	0.85	0.37	0.29	0.46	0.4	0.29	0.63	0.49	0.43	0.47	0.38		0.4	0.18	0.19	0.46	0.42	0.7	0.21	-0.63	0.78	0.46	0.43	0.25	0.6
Total Liab	1.0	0.69	1.0	0.97	0.99	0.99	0.96	0.79	0.75	1.0	0.92	0.99	0.4		0.66	0.79	0.99	0.98	0.86	0.85	-0.55	0.71	0.91	0.93	0.92	0.88
Intangible Assets	0.69	0.49	0.67	0.75	0.67	0.68	0.79	0.38	0.36	0.66	0.59	0.68	0.18	0.66		0.78	0.67	0.66	0.56	0.6	-0.21	0.39	0.51	0.51	0.61	0.46
Common Stock	0.83	0.4	0.8	0.9	0.79	0.85	0.91	0.59	0.46	0.8	0.58	0.85	0.19	0.79	0.78		0.78	0.76	0.61	0.61	-0.25	0.32	0.6	0.63	0.65	0.53
Property Plant Equipment	0.99	0.73	0.99	0.96	0.99	0.98	0.95	0.81	0.73	0.99	0.91	0.97	0.46	0.99	0.67	0.78		0.99	0.87	0.86	-0.55	0.74	0.92	0.93	0.9	0.89
Other Liab	0.98	0.69	0.98	0.95	0.98	0.96	0.94	0.75	0.68	0.98	0.88	0.96	0.42	0.98	0.66	0.76	0.99		0.83	0.87	-0.47	0.7	0.92	0.92	0.9	0.87
Good Will	0.85	0.92	0.84	0.79	0.88	0.85	0.78	0.82	0.8	0.87	0.88	0.85	0.7	0.86	0.56	0.61	0.87	0.83		0.73	-0.76	0.81	0.88	0.91	0.83	0.95
Net Tangible Assets	0.85	0.62	0.86	0.82	0.85	0.82	0.82	0.57	0.53	0.84	0.77	0.81	0.21	0.85	0.6	0.61	0.86	0.87	0.73		-0.3	0.53	0.91	0.88	0.95	0.81
Other Stockholder Equity	-0.51	-0.73	-0.51	-0.4	-0.52	-0.51	-0.43	-0.78	-0.83	-0.56	-0.76	-0.53	-0.63	-0.55	-0.21	-0.25	-0.55	-0.47	-0.76	-0.3		-0.81	-0.58	-0.65	-0.49	-0.73
Deferred Long Term Liab	0.66	0.88	0.67	0.54	0.7	0.64	0.59	0.74	0.74	0.7	0.85	0.64	0.78	0.71	0.39	0.32	0.74	0.7	0.81	0.53	-0.81		0.72	0.72	0.59	0.82
Long Term Investments	0.89	0.77	0.9	0.83	0.9	0.87	0.82	0.8	0.71	0.9	0.86	0.87	0.46	0.91	0.51	0.6	0.92	0.92	0.88	0.91	-0.58	0.72		0.98	0.93	0.96
Short Long Term Debt	0.92	0.75	0.92	0.86	0.92	0.9	0.84	0.81	0.81	0.93	0.9	0.91	0.43	0.93	0.51	0.63	0.93	0.92	0.91	0.88	-0.65	0.72	0.98		0.95	0.97
Total Current Assets	0.92	0.66	0.92	0.88	0.91	0.89	0.87	0.66	0.68	0.91	0.88	0.9	0.25	0.92	0.61	0.65	0.9	0.9	0.83	0.95	-0.49	0.59	0.93	0.95		0.88
Short Term Debt	0.85	0.87	0.86	0.77	0.88	0.84	0.77	0.83	0.81	0.88	0.89	0.84	0.6	0.88	0.46	0.53	0.89	0.87	0.95	0.81	-0.73	0.82	0.96	0.97	0.88

Click cells to compare fundamentals

Shanghai Pharmaceuticals Account Relationship Matchups

Shanghai Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	137.0B	149.2B	163.4B	198.1B	212.0B	222.6B
Other Current Liab	8.0B	9.5B	9.7B	6.4B	6.3B	3.5B
Total Current Liabilities	74.6B	88.1B	91.8B	110.7B	122.4B	128.5B
Total Stockholder Equity	41.7B	45.4B	49.4B	67.1B	68.5B	72.0B
Retained Earnings	23.6B	26.9B	30.6B	34.6B	33.8B	35.5B
Accounts Payable	36.9B	37.8B	42.0B	51.6B	54.6B	57.4B
Cash	18.2B	22.3B	22.4B	27.4B	30.5B	32.0B
Other Assets	2.9B	5.7B	2.8B	3.0B	3.5B	3.7B
Long Term Debt	9.1B	1.2B	7.2B	6.3B	5.8B	6.1B
Net Receivables	51.3B	52.7B	58.1B	66.8B	72.9B	76.6B
Inventory	24.9B	24.1B	27.1B	34.5B	36.6B	38.5B
Other Current Assets	3.7B	4.3B	4.2B	1.4B	1.4B	1.5B
Total Liab	87.6B	94.4B	104.4B	120.1B	131.6B	138.2B
Intangible Assets	4.1B	5.4B	6.3B	6.6B	6.4B	6.7B
Property Plant Equipment	10.6B	13.1B	14.6B	15.8B	18.2B	19.1B
Other Liab	2.1B	2.7B	3.6B	4.0B	4.5B	4.8B
Good Will	10.8B	11.3B	11.2B	11.3B	11.4B	7.3B
Net Tangible Assets	23.6B	26.9B	28.8B	32.1B	36.9B	28.6B
Other Stockholder Equity	(492.6M)	(542.2M)	(265.4M)	(144.4M)	(130.0M)	(136.5M)
Deferred Long Term Liab	606.4M	639.1M	688.3M	342.6M	394.0M	504.8M
Short Long Term Debt	23.1B	20.1B	22.5B	27.8B	35.6B	21.0B
Total Current Assets	98.1B	107.6B	116.5B	149.5B	162.4B	111.5B
Non Current Assets Total	38.9B	41.6B	46.9B	48.6B	49.5B	42.3B
Non Currrent Assets Other	3.3B	12.6B	856.9M	443.8M	440.7M	418.7M
Non Current Liabilities Total	13.0B	6.3B	12.5B	9.4B	9.3B	9.9B
Non Current Liabilities Other	190.9M	170.4M	566.1M	257.3M	250.1M	274.1M
Net Debt	10.3B	14.1B	7.3B	6.6B	10.8B	9.3B
Net Invested Capital	73.9B	66.7B	79.0B	101.1B	109.9B	86.3B
Net Working Capital	23.5B	19.4B	24.7B	38.8B	40.1B	29.9B

Currently Active Assets on Macroaxis

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C
MSFT	Microsoft
GM	General Motors

Other Information on Investing in Shanghai Stock

Balance Sheet is a snapshot of the financial position of Shanghai Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Shanghai Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Shanghai Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Shanghai currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Shanghai Long Term Debt vs Good Will Analysis

Long Term Debt vs Good Will

Long Term Debt vs Good Will Correlation Analysis

Correlation Coefficient

Long Term Debt

Good Will

Shanghai Pharmaceuticals fundamental ratios Correlations

Shanghai Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Shanghai Pharmaceuticals fundamental ratios Accounts

Currently Active Assets on Macroaxis

Other Information on Investing in Shanghai Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Liabilities	+ 1.0	Total Assets
Net Receivables	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Assets
Net Receivables	+ 1.0	Total Current Liabilities
Total Liab	+ 1.0	Total Current Liabilities
Inventory	+ 1.0	Accounts Payable

Other Stockholder Equity	- 0.83	Long Term Debt
Deferred Long Term Liab	- 0.81	Other Stockholder Equity
Other Stockholder Equity	- 0.78	Other Assets
Other Stockholder Equity	- 0.76	Good Will
Other Stockholder Equity	- 0.76	Short Term Investments
Short Term Debt	- 0.73	Other Stockholder Equity